These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 16540421

  • 1. PCTH: a novel orally active chelator for the treatment of iron overload disease.
    Lovejoy DB, Kalinowski D, Bernhardt PV, Richardson DR.
    Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
    [Abstract] [Full Text] [Related]

  • 2. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
    Lim CK, Kalinowski DS, Richardson DR.
    Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
    [Abstract] [Full Text] [Related]

  • 3. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
    Wong CS, Kwok JC, Richardson DR.
    Biochim Biophys Acta; 2004 Dec 24; 1739(1):70-80. PubMed ID: 15607119
    [Abstract] [Full Text] [Related]

  • 4. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
    Becker E, Richardson DR.
    J Lab Clin Med; 1999 Nov 24; 134(5):510-21. PubMed ID: 10560945
    [Abstract] [Full Text] [Related]

  • 5. Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity.
    Bernhardt PV, Chin P, Sharpe PC, Richardson DR.
    Dalton Trans; 2007 Aug 14; (30):3232-44. PubMed ID: 17893768
    [Abstract] [Full Text] [Related]

  • 6. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy.
    Bernhardt PV, Chin P, Richardson DR.
    J Biol Inorg Chem; 2001 Oct 14; 6(8):801-9. PubMed ID: 11713687
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
    Kalinowski DS, Richardson DR.
    Chem Res Toxicol; 2007 May 14; 20(5):715-20. PubMed ID: 17402750
    [Abstract] [Full Text] [Related]

  • 9. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.
    Becker EM, Lovejoy DB, Greer JM, Watts R, Richardson DR.
    Br J Pharmacol; 2003 Mar 14; 138(5):819-30. PubMed ID: 12642383
    [Abstract] [Full Text] [Related]

  • 10. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
    Richardson DR, Ponka P.
    J Lab Clin Med; 1994 Nov 14; 124(5):660-71. PubMed ID: 7964124
    [Abstract] [Full Text] [Related]

  • 11. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
    Santos MA, Gama S, Gil M, Gano L.
    Hemoglobin; 2008 Nov 14; 32(1-2):147-56. PubMed ID: 18274992
    [Abstract] [Full Text] [Related]

  • 12. Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
    Liu J, Obando D, Schipanski LG, Groebler LK, Witting PK, Kalinowski DS, Richardson DR, Codd R.
    J Med Chem; 2010 Feb 11; 53(3):1370-82. PubMed ID: 20041672
    [Abstract] [Full Text] [Related]

  • 13. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
    Donovan JM, Plone M, Dagher R, Bree M, Marquis J.
    Ann N Y Acad Sci; 2005 Feb 11; 1054():492-4. PubMed ID: 16339704
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
    Chaston TB, Richardson DR.
    Am J Hematol; 2003 Jul 11; 73(3):200-10. PubMed ID: 12827659
    [Abstract] [Full Text] [Related]

  • 16. Potent antimycobacterial activity of the pyridoxal isonicotinoyl hydrazone analog 2-pyridylcarboxaldehyde isonicotinoyl hydrazone: a lipophilic transport vehicle for isonicotinic acid hydrazide.
    Ellis S, Kalinowski DS, Leotta L, Huang ML, Jelfs P, Sintchenko V, Richardson DR, Triccas JA.
    Mol Pharmacol; 2014 Feb 11; 85(2):269-78. PubMed ID: 24243647
    [Abstract] [Full Text] [Related]

  • 17. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease.
    Richardson DR, Ponka P.
    J Lab Clin Med; 1998 Apr 11; 131(4):306-15. PubMed ID: 9579383
    [Abstract] [Full Text] [Related]

  • 18. Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs.
    Richardson DR, Ponka P.
    J Lab Clin Med; 1998 Oct 11; 132(4):351-2. PubMed ID: 9794707
    [No Abstract] [Full Text] [Related]

  • 19. Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics.
    Liu G, Men P, Kenner GH, Miller SC, Bruenger FW.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct 11; 23(3):599-611. PubMed ID: 15113026
    [Abstract] [Full Text] [Related]

  • 20. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
    Whitnall M, Richardson DR.
    Semin Pediatr Neurol; 2006 Sep 11; 13(3):186-97. PubMed ID: 17101458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.